baber/WOPTO huggingface dataset:
Patent NZ-561213-A (NZ)
Title: Dispersions stabilised by cross-linked polymeric dispersants
Inventor: SHIRLEY IAN MALCOLM
IPC: C09K23/52
Filed: 2006-03-10
Abstract: Disclosed is a dispersion of an agrochemical which is either an agrochemical active ingredient or an agrochemical adjuvant, said dispersion comprising a discontinuous phase of solid particles comprising the agrochemical or liquid droplets comprising the agrochemical which have an average diameter of between 1000 microns and 0.1 microns; a liquid continuous phase; a polymeric dispersant physically adsorbed at the interface between the continuous phase and the discontinuous phase, having a segment soluble in the continuous phase and a segment insoluble in the continuous phase; and a network around the solid particles or the liquid droplets formed by cross-linking of the polymeric dispersant; where the cross-linking involves a reactive moiety located within the segment that is soluble in the continuous phase.
Patent NZ-564140-A (NZ)
Title: Tool with non-slip feature or friction assembly
Inventor: HOBDEN ROBERT J
Filed: 2007-12-10
Abstract: A variable friction assembly for various tools is disclosed. The assembly incorporates materials (22, 24) with a high coefficient of friction and a low coefficient of friction. The materials with a low coefficient of friction may be mounted on a tool (10) and have a retraction mechanism. This retraction mechanism may be implemented with a spring (46). The materials with a high coefficient of friction may be mounted on the tool in a fixed position. The tool may be pressed against a surface, first engaging the materials with a low coefficient of friction. The tool may freely move across the surface while the materials with a low coefficient of friction maintain contact with the surface. As the tool is pressed to the surface, the materials with a high coefficient of friction subsequently make contact with the surface, thereby causing the lateral movement of the tool with respect the surface to be restricted and stabilized. An example of the tool may be a spirit or carpenter level.
Patent NZ-565080-A (NZ)
Title: Novel heterocyclidene acetamide derivative
Inventor: UCHIDA HIDEHARU
IPC: A61K31/4155
Filed: 2006-07-24
Abstract: Disclosed is a 3, 4-dihydrobenzo[b[oxepin-5(2H)-ylidine represented by formula (I'-D), or a salt thereof, wherein each of A1, A2, A3 and A4 is -CH=; m' represent an integer of 1 or 2; n and p each independently represent an integer of 0 to 2; wherein R1, Q' is defined in the specification, y is 0, 1, 2, or 3 and wherein the wavy line in formula (I'-D) represents an E isomer or a Z-isomer. Also disclosed is pharmaceutical compositions comprising said ylidine and the use of said ylidine in the treatment of pain.
Patent NZ-567764-A (NZ)
Title: Segmented dome enclosure
Inventor: ZITKO JAN
IPC: E04B1/32
Filed: 2006-10-03
Abstract: An enclosure, especially for a spa, has the shape of a bowl and includes a sliding door. The enclosure contains several segments (A), each of them created by frame (1), with transparent plates (2) inside. The lower part of segments (A) is located on a circular or oval running track (3) which is placed on the ground. The tops of segments (A) are separably connected to the edge of surface (B), having the shape of a bowl. A sliding door (C), between the edge of surface (B) and lower running track (3), includes at least one leaf.
Patent NZ-571226-A (NZ)
Title: Methods and compositions for the repair and/or regeneration of damaged myocardium
Inventor: ANVERSA PIERO
IPC: A61K35/12
Filed: 2007-02-15
Abstract: Disclosed is the use of isolated cardiac stem cells and one or more growth factors in the manufacture of a medicament for the treatment of a vasculature disorder, wherein the medicament is capable of forming a large coronary vessel or artery in a patient following administration, and wherein the cardiac stem cells are to be activated by exposure to the one or more growth factors prior to administration of the medicament to the patient, and wherein the one or more growth factors is selected from Activin A, Angiotensin II, Bone Morphogenic Protein 2, Bone Morphogenic Protein 4, Bone Morphogenic Protein 6, Cardiotrophin-l, FIbroblast Growth Factor 1, Fibroblast Growth Factor 4, FIt3 Ligand, Glial-Derived Neurotrophic Factor, Heparin, Hepatocyte Growth Factor, Insulin-like Growth Factor-I, Insulin-like Growth Factor-II, Insulin-Like Growth Factor Binding Protein-3, Insulin-Like Growth Factor Binding Protein-S, Interleukin-3, Interleukin-6, Interlekin-8, Leukemia Inhibitory Factor, Midkine, Platelet-Derived Growth Factor AA, Platelet-Derived Growth Factor BB, Progesterone, Putrescine, Stem Cell Factor, Stromal-Derived Factor-I, Thrombopoietin, Transforming Growth Factor-á, Transforming Growth Factor-â1, Transforming Growth Factor-â2, Transforming Growth Factor-â3, Vascular Endothelial Growth Factor, Wnt!, Wnt3a, and Wnt5a, and a combination thereof.
Patent NZ-576312-A (NZ)
Title: Antimicrobial composition comprising propiconazole and 3-iodo-2-propynyl-butylcarbamate
Inventor: ASHMORE JOHN WILLIAM
IPC: A01N33/04
Filed: 2006-06-08
Abstract: Disclosed is a synergistic antimicrobial composition comprising propiconazole and 3-iodo-2-propynyl-butylcarbamate, in a weight ratio of between 1:0.0007 and 1:0.011. Also disclosed is a method of using the above composition to inhibit the growth of microorganisms. (62) Divided Out of 563783
Patent NZ-578744-A (NZ)
Title: 2-aminopyridine derivatives useful as kinase inhibitors
Inventor: JIMENEZ JUAN-MIGUEL
IPC: C07D401/14
Filed: 2008-01-30
Abstract: Disclosed are (2-aminopyridin-3-yl)(heteroaryl)methanone derivatives as represented by the general formula, wherein B is a monocyclic heteroaromatic ring, a 6,6 bicyclic heteroaromatic ring, or a 6,5 bicyclic heteroaromatic ring wherein B is optionally and independently substituted with R12' and independently optionally and independently substituted with one or more R12 groups in addition to R3; Z is O or S; R1 is hydrogen, halogen, cyano, nitro, or -T1-Q1; R2 is hydrogen, halogen, cyano, nitro or optionally and independently substituted alkyl; R3 is halogen, cyano, nitro, or -T2-Q2; and wherein the remaining substituents are as defined herein. Further disclosed is a composition which comprises a compound of pharmaceutically acceptable salt thereof as defined above, and a pharmaceutically acceptable carrier, adjuvant, or vehicle for treating or preventing a protein kinase-mediated condition and particularly a GSK 3 mediated condition such as diabetes, Alzheimer's disease, Huntington's disease, Parkinson's disease, AIDS-associated dementia, bipolar disorder, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, leukocytopenia, cardiomyocyte hypertrophy, stroke, and rheumatoid arthritis.
Patent NZ-579196-A (NZ)
Title: Fixing equipment in a sewer pipe by compressing and inserting a split pipe to grip the inside when released
Inventor: FRITZBOGER PREBEN
IPC: A01M27/00
Filed: 2008-02-06
Abstract: A method and a mounting for the installation of powered equipment (1) in front of a sewer pipe opening (41) in a sewer shaft (50) is disclosed. Broadly speaking the method of installing the powered equipment includes mounting the powered equipment on the console which includes a resilient tubular member (40) shaped to be of a diameter slightly larger than the inside diameter of the pipe. The tubular member is them compressed such that it may be inserted in to the pipe. Releasing the tubular member allows it to expand to engage with the inside of the sewer pipe opening. A powered equipment assembly is also disclosed. One example of the utility of this assembly is to act as a trap for rats using spikes (3) and/or a monitoring station.
Patent NZ-587103-A (NZ)
Title: Thermodynamic cycle and method of operation where vapor of the working fluid bypasses the expansion device in order to start the circuit.
Inventor: LENGERT JORG
IPC: F01K25/06
Filed: 2008-12-03
Abstract: A thermodynamic circuit (1) and method of operating a thermodynamic circuit are disclosed. The circuit (1) comprises a first heat exchanger (W1) for producing a first heated or partially vaporized working medium flow (15) by heat transfer from an expanded working medium flow (12). A second heat exchanger (W2) produces a second at least partially vaporized working medium flow (18) from the first flow (15) with heat transferred from an external source (20). A separator separates a liquid phase (19) from the second working medium flow (19) and the vapour phase (10) is expanded by expansion device (2) such as a turbine. The liquid phase (19) and expanded vapour (11) are combined in the expanded working medium (12) and a third heat exchanger (W3) completely condenses the expanded working medium flow (12) after it passes through the first heat exchanger (W1). To start the circuit the vapour phase (10) bypasses (31) the expansion device (2) and the first heat exchanger (W1) to combine (35) with the cooled down working medium flow (12a) after the first heat exchanger (W1).
Patent NZ-591530-A (NZ)
Title: Interruption of measured variable analyses in an automatic water softening system when defined operating situations are present
Inventor: NEIDHARDT KLAUS
IPC: B01J47/14
Filed: 2009-08-13
Abstract: 591530 Disclosed is a water softening system (1). The system (1) includes an automatically adjustable blending means (9) for mixing a blended water flow Vblended(t) from a first softened partial flow V(t)part1soft and a second untreated water partial flow V(t)part2raw. An electronic control means (19) is included that has with a storage (5). The control means (19) is designed to readjust the adjustment position of the blending means (9) by means of one or more experimentally determined instantaneous measured values in such a fashion that the water hardness in the blended water flow is adjusted to a predetermined desired value (SW). The storage (5) includes one or more stored defined operating situations of the water softening system (1), upon occurrence of which at least one of the one or more instantaneous measured values for readjustment of the adjustment position of the blending means (9) is ignorable by the control means (19). The electronic control means (19) also includes a stored standard value for the at least one instantaneous measured value or a stored respectively last corresponding measured value that was valid prior to occurrence of the defined operating situation. Readjustment of the adjustment position of the blending means (9) occurs based upon the stored standard value for the at least one instantaneous measured value or the stored respectively last corresponding measured value.
Patent NZ-595205-A (NZ)
Title: Float valve for a watering trough, the outlet having a connector which allows releasable coupling of a conduit
Inventor: CRICHTON DAVID GORDON ARTHUR
IPC: A01K7/04
Filed: 2012-08-17
Abstract: Disclosed is a lever (3) mounted float (9) operated liquid control valve particularly suited for use with animal watering troughs that are typically sited some considerable distance from their water source. The valve incorporates an outlet (8) adapted, such as by groove (8b), to have a detachable conduit coupling connected thereto enabling temporary branches or take-offs to be connected thereto. The outlet (8) is preferably designed to enable coupling with an overcentre cam coupling and is preferably in the nature of a removable cap. In addition locking means (2) are provided enabling the valve to be maintained in a closed mode while the coupling is connected to and disconnected from the valve. The valve is preferably of a type wherein a float lever (3) thereof impinges with a bridging section (5c) of an opening and closing plunger (5) mounted in an associated cylinder of the valve. Further characterising the invention the bridging section (5c) is set-back from the side of the plunger (5) associated with the lever (3). This enables, with removal of the outlet cap (8), the plunger (5) to be displaced sufficiently to provide clearance between the plunger (5) and the lever (3) enabling removal of the plunger (5) without disconnecting the lever (3) from the valve body (1). This facilitates cleaning of the valve. Also the outlet (8) preferably includes a bore (11) with a middle section (11c) between, relative to the middle section (11c), an inner converging section (11a) and an outer diverging section (11b).
Patent NZ-603043-A (NZ)
Title: Pharmaceutical compositions comprising cftr modulators and administrations thereof
Inventor: SHETH URVI JAGDISHBHAI
IPC: C07D317/46
Filed: 2011-04-22
Abstract: Disclosed is a pharmaceutical composition comprising: Compound 1 SDD Formulation and Compound 3 Form I Tablet Formulation wherein: Compound 1 SDD Formulation is a spray dried dispersion of ivacaftor (VX-770), which comprises from about 45 wt% to about 85 wt% of substantially amorphous ivacaftor by weight of the dispersion, from about 14.45 wt% to about 55.55 wt% of hydroxypropylmethylcellulose acetate succinate (HPMCAS) by weight of the dispersion, and from about 0.45 wt% to about 0.55 wt% sodium lauryl sulfate (SLS) by weight of the dispersion; Compound 3 Form I Tablet Formulation comprises: crystalline form I of lumacaftor (VX-809) (characterized by one or more peaks at 15.2 to 15.6 degrees, 16.1 to 16.5 degrees, and 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation) in an amount ranging from about 20 wt% to about 80 wt% by weight of the composition; a filler comprising microcrystalline cellulose in an amount ranging from about 20 wt% to about 50 wt% by weight of the composition; a disintegrant comprising sodium croscarmellose sodium in an amount ranging from about 1 wt% to about 5 wt% by weight of the composition; a surfactant comprising sodium lauryl sulfate in an amount ranging from about 2 wt% to about 0.3 wt% by weight of the composition; a diluent comprising mannitol in an amount ranging from about 1 wt% to about 30 wt% by weight of the composition; a lubricant comprising magnesium stearate in an amount ranging from about 0.3 wt% to about 5 wt% by weight of the composition; and at least one of: a binder comprising polyvinylpyrrolidone in an amount ranging from about 0.1 wt% to about 5 wt% by weight of the composition and a glidant comprising colloidal silica in an amount ranging from about 0.05 wt% to about 2 wt% by weight of the composition. Also disclosed is the use of the pharmaceutical composition as defined above in the manufacture of a medicament for treating a CFTR mediated disease in a human, wherein the CFTR mediated disease is selected from cystic fibrosis, COPD, emphysema, dry-eye disease or osteoporosis.
Patent NZ-607605-A (NZ)
Title: Hand trolley
Inventor: TRAPNELL KEVIN EDWARD
IPC: B62B5/00
Filed: 2011-08-22
Abstract: A hand trolley (200) including a main body (202) and a lifting platform (210) movable relative to the main body for lifting a load. A force applied by the foot of an operator (to foot platform 602) is used to lift the platform (210). The lifting may occur in multiple stages to raised the platform to a working height. The distance moved by the platform is substantially equal to the movement of the users foot.
Patent NZ-608972-A (NZ)
Title: Engineered nucleic acids and methods of use thereof
Inventor: SCHRUM JASON
IPC: C12N15/09
Filed: 2011-10-03
Abstract: Disclosed is a method of producing a heterologous protein of interest in a cell in vitro, comprising introducing into a target cell capable of protein translation a composition comprising a first isolated nucleic acid comprising a translatable region encoding a heavy chain of the heterologous protein of interest and a second isolated nucleic acid comprising a translatable region encoding a light chain of the heterologous protein of interest, under conditions such that the protein of interest is produced in the cell, wherein the protein of interest is an immunoglobulin protein, wherein the first isolated nucleic acid comprises a nucleotide sequence having at least 95% identity to SEQ ID NO: 9, wherein the second isolated nucleic acid comprises a nucleotide sequence having at least 95% identity to SEQ ID NO: 11, wherein the first isolated nucleic acid and the second isolated nucleic acid are not linked and each of the first isolated nucleic acid and the second isolated nucleic acid comprise at least one nucleoside modification, wherein the sequences are as disclosed in the complete specification.
Patent NZ-615675-A (NZ)
Title: Method for designing a mould for casting a semi-finished ophthalmic lens blank, method for assembling a mould assembly, method for casting a semi-finished phthalmic lens blank and computer program product for carrying out said methods
Inventor: REGO CARLOS
IPC: B29D11/00
Filed: 2012-03-22
Abstract: Disclosed is a method for designing a mould (12, 14) for casting a semi-finished ophthalmic lens blank. The surface of the mould (12, 14) is designed so that the surface of the mould (12, 14) substantially fits a predetermined closed curve representative of the geometry of a gasket (16) to be used in combination with the mould (12, 14). The surface of the mould (12, 14) is designed using an optimisation process and the predetermined closed curve being a constraint for the optimisation process.
Patent NZ-617632-A (NZ)
Title: Electrical heater with particular application to humidification and fluid warming
Inventor: ROW NATHAN JOHN
IPC: H05B3/48
Filed: 2008-06-03
Abstract: A tub (50) for a humidifier configured to humidify a flow of breathable gas, the tub being configured to hold a supply of water, the tub comprising: an inlet (120) to receive the flow of breathable gas; an outlet (122) to deliver the humidified flow of breathable gas; and a water level detection means comprising a first conductive portion (ink 44) and configured to indicate a water level of the supply of water based on determination of electrical conductivity between the first conductive portion and the supply of water.
Patent NZ-618590-A (NZ)
Title: Handling redundant data in a communication system
Inventor: JONSSON ANDERS
IPC: H04L1/18
Filed: 2012-10-31
Abstract: Disclosed is a method in a radio network controller (105) for transmitting a discard indication signal. The radio network controller configured for multi-point High Speed Downlink Packet Access (HSDPA) operation wherein data is communicated to a first user equipment (106) via at least two radio base stations (104). The method comprises transmitting a discard indication signal to at least one of the at least two radio base stations. The discard indication signal includes a first data frame sequence number and wherein the discard indication signal indicates to the at least one radio base station that Medium Access Control protocol handling dedicated data Protocol Data Units (MAC-d PDUs) received by the at least one radio base station from the radio network controller in a data frame associated with the first data frame sequence number can be discarded.
Patent NZ-625907-A (NZ)
Title: Building foundation system
Inventor: HAMBLING JONATHAN LESLIE
IPC: E04B5/32
Filed: 2013-08-30
Abstract: A building foundation system (100) comprising: a building base portion (2) comprising a substantially uniform concrete upper portion with integral beam elements created below the upper portion; a foundation base portion (1) comprising a concrete slab; a plurality of lifting means (10) engaged with the building base portion, each lifting means comprising an internally threaded portion adapted for threaded engagement with an externally threaded member; the foundation base portion provided with a bearing plate for each lifting means. Each internally threaded portion is accessible from above the building base portion to allow, in use, engagement of a respective externally threaded member with the internally threaded portion, rotation of the externally threaded member and bearing of the externally threaded member against a respective bearing plate, and consequent lifting of the building base portion relative to the foundation base portion.
Patent NZ-701398-A (NZ)
Title: Dietary management of celiac disease and food allergy
Inventor: TANBONLIONG GRETCHEN
IPC: A23L33/00
Filed: 2013-05-22
Abstract: The present disclosure provides compositions and methods for dietary management of celiac disease and food allergy in a subject, such as a formula-fed infant, via enteral administration of an effective amount of at least one hydrolyzed protein and Lactobacillus rhamnosus GG (LGG). The inventive nutritional compositions may contain a hydrolyzed protein component, a lipid component, a carbohydrate component, a vitamin component, a mineral component, and a prebiotic component in addition to a probiotic component, which comprises an effective amount of LGG.
Patent NZ-720022-A (NZ)
Title: Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
Inventor: NARAIN NIVEN
IPC: A61P35/00
Filed: 2011-03-11
Abstract: Disclosed is a therapeutic formulation suitable for intravenous administration to a subject comprising: an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent ; wherein the colloidal nano-dispersion of the active agent is dispersed into nanodispersion particles having a mean size of less than 200-nm. In a preferred embodiment the hydrophobic active agent is coenzyme Q10 (CoQ10) and the dispersion stabilizing agent is dimyristoylphosphatidyl choline (DMPC).
Patent NZ-721406-A (NZ)
Title: Use of polylactide and method of manufacturing a heat-sealed paper or board container or package
Inventor: NEVALAINEN KIMMO
IPC: B32B27/10
Filed: 2015-01-22
Abstract: The invention relates to use of polylactide (PLA) as an extruded polymer coating on paper or board intended for the production of containers and packages, which are heated in a stove or microwave oven. According to the invention a polyfunctional cross-linking agent, such as trialkyl isocyanureate (TAIC), is blended with PLA, and the extruded coating layer is subjected to cross-linking electron beam (EB) radiation. PLA may be used as such or blended with another biodegradable polyester such as polybutylene succinate (PBS). EB radiation has been found to improve adhesion of the coating to the paper or board substrate, heat-sealability of the coating, and heat- resistance of the finished containers and packages.
Patent NZ-722391-A (NZ)
Title: Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
Inventor: NG AUSTEN
IPC: C07K14/755
Filed: 2015-02-04
Abstract: The present invention relates to improved methods in the separation recombinant polypeptides with post-translational modifications from complex mixtures through the use of a cation exchange medium.
Patent NZ-724904-A (NZ)
Title: Hybrid immunoglobulin containing non-peptidyl linkage
Inventor: CAPON DANIEL
IPC: A61K31/05
Filed: 2015-03-13
Abstract: The present invention provides a compound having the structure: wherein A is a biologically active structure of the compound; wherein Z is a protein component of the compound, which protein component comprises one or more polypeptides, wherein at least one of the one or more polypeptides comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine or selenocysteine; wherein the dashed line between B and Z represents a peptidyl linkage; and wherein the solid line between A and B represents a nonpeptidyl linkage, as well as intermediates dimers thereof, and processes of producing the compounds of the invention. The specification describes said immunoglobulins wherein Z is linked at an N-terminal cysteine or selenocysteine residue to “B” via a peptidyl linkage, rather than the C-terminus as is usual.